Lumbricus rubellus extract

Generic Name: Lumbricus rubellus extract

Clinical Trials

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Phase 2

Conditions: Ischemic Stroke

Interventions: Drug: DLBS1033
Drug: Aspirin
Drug: Statin
Drug: Vit B12

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-11

Lead Sponsor: Duta Wacana Christian University

Target Recruit Count: 180

Registration Number: NCT04425590

Locations: 🇮🇩
Bethesda Hospital Yogyakarta, Yogyakarta, Special Region Of Yogyakarta, Indonesia

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Phase 2

Terminated

Conditions: ST Elevation Myocardial Infarction

Interventions: Drug: Placebo
Drug: DLBS1033
Drug: Standard therapy

First Posted Date: 2016-11-29

Last Posted Date: 2023-09-08

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 23

Registration Number: NCT02976701

Locations: 🇮🇩
Binawaluya Cardiac Hospital, Jakarta, Indonesia

DLBS1033 for the Treatment of Acute Ischemic Stroke

Phase 3

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Drug: Placebo
Drug: DLBS1033

First Posted Date: 2015-02-13

Last Posted Date: 2017-05-04

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 9

Registration Number: NCT02362984

Locations: 🇮🇩
RSUD R. Syamsudin, SH, Sukabumi, West Java, Indonesia

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Phase 2

Withdrawn

Conditions: Acute Non-ST Elevation Myocardial Infarction

Interventions: Drug: Placebo
Drug: DLBS1033

First Posted Date: 2014-05-26

Last Posted Date: 2016-04-20

Lead Sponsor: Dexa Medica Group

Registration Number: NCT02146664

Locations: 🇮🇩
Binawaluya Cardiac Hospital, Jakarta, Indonesia
🇮🇩
Central Army Hospital RSPAD Gatot Soebroto, Central Jakarta, Jakarta, Indonesia

DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Phase 2

Terminated

Conditions: Diabetes
Peripheral Arterial Disease

Interventions: Drug: DLBS1033
Drug: Placebo

First Posted Date: 2014-05-23

Last Posted Date: 2018-07-26

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 11

Registration Number: NCT02145988

Locations: 🇮🇩
Department of Internal Medicine, Faculty of Medicine, University of Udayana/Sanglah Hospital, Denpasar, Bali, Indonesia
🇮🇩
Department of Internal Medicine, RSUD Wangaya, Denpasar, Bali, Indonesia

DLBS1033 for Acute Ischemic Stroke Patients

Phase 2

Terminated

Conditions: Acute Ischemic Stroke
Partial Anterior Circulation Infarct
Lacunar Anterior Circulation Infarct

Interventions: Drug: Placebo
Drug: DLBS1033

First Posted Date: 2014-05-08

Last Posted Date: 2023-12-12

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 80

Registration Number: NCT02133521

Locations: 🇮🇩
Neurology Department Islam Jakarta Hospital (RSIJ) Cempaka Putih, Jakarta Pusat, DKI Jakarta, Indonesia
🇮🇩
Neurology Department, Budhi Asih Hospital, Jakarta, DKI Jakarta, Indonesia
🇮🇩
Universitas Sebelas Maret (UNS) Hospital, Sukoharjo, Central Java, Indonesia

and more 7 locations

Biological Half Life of DLBS1033 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Condition

Interventions: Drug: DLBS1033

First Posted Date: 2013-07-23

Last Posted Date: 2017-05-12

Lead Sponsor: Indonesia University

Target Recruit Count: 14

Registration Number: NCT01905878

Locations: 🇮🇩
University of Indonesia, Jakarta, Indonesia

Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: placebo tablet of DLBS1033
Drug: DLBS1033

First Posted Date: 2013-05-31

Last Posted Date: 2016-08-04

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 122

Registration Number: NCT01865474

Locations: 🇮🇩
Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital, Padang, Sumatera Barat, Indonesia

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Phase 3

Completed

Conditions: Acute Ischemic Stroke

Interventions: Drug: DLBS1033
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2013-02-13

Last Posted Date: 2014-06-04

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 126

Registration Number: NCT01790997

Locations: 🇮🇩
Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital, Yogyakarta, Jogjakarta, Indonesia

The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: DLBS1033
Drug: placebo

First Posted Date: 2012-09-27

Last Posted Date: 2017-05-15

Lead Sponsor: Indonesia University

Target Recruit Count: 21

Registration Number: NCT01694537

Locations: 🇮🇩
Indonesia University, Jakarta, Indonesia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy